Next Article in Journal
A SiPM-Enabled Portable Delayed Fluorescence Photon Counting Device: Climatic Plant Stress Biosensing
Next Article in Special Issue
In Vivo Biomarker Imaging: Paving the Way for Precision Medicine
Previous Article in Journal
Critical Design Factors for Electrochemical Aptasensors Based on Target-Induced Conformational Changes: The Case of Small-Molecule Targets
Previous Article in Special Issue
The Dual-Targeted Peptide Conjugated Probe for Depicting Residual Nasopharyngeal Carcinoma and Guiding Surgery
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Toward In Vivo MRI of the Tissue Proton Exchange Rate in Humans

1
Department of Radiology, University of Illinois at Chicago, Chicago, IL 60612, USA
2
Department of Biomedical Engineering, University of Illinois at Chicago, Chicago, IL 60607, USA
*
Author to whom correspondence should be addressed.
Biosensors 2022, 12(10), 815; https://doi.org/10.3390/bios12100815
Submission received: 22 July 2022 / Revised: 19 September 2022 / Accepted: 29 September 2022 / Published: 1 October 2022
(This article belongs to the Special Issue In Vivo Imaging and Sensing of Biomarkers)

Abstract

:
Quantification of proton exchange rate (kex) is a challenge in MR studies. Current techniques either have low resolutions or are dependent on the estimation of parameters that are not measurable. The Omega plot method, on the other hand, provides a direct way for determining kex independent of the agent concentration. However, it cannot be used for in vivo studies without some modification due to the contributions from the water signal. In vivo tissue proton exchange rate (kex) MRI, based on the direct saturation (DS) removed Omega plot, quantifies the weighted average of kex of the endogenous tissue metabolites. This technique has been successfully employed for imaging the variation in the kex of ex vivo phantoms, as well as in vivo human brains in healthy subjects, and stroke or multiple sclerosis (MS) patients. In this paper, we present a brief review of the methods used for kex imaging with a focus on the development of in vivo kex MRI technique based on the DS-removed Omega plot. We then review the recent clinical studies utilizing this technique for better characterizing brain lesions. We also outline technical challenges for the presented technique and discuss its prospects for detecting tissue microenvironmental changes under oxidative stress.

1. Introduction

Chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) is an emerging imaging technique for noninvasive imaging of the endogenous metabolites in tissue, which includes proteins, peptides, amino acids, and other small molecules. In this MRI technique, the contrast is created by the exchange of the selectively saturated exchanging protons with water protons. The exchanging protons can be those in the tissue metabolites, in their amine –NH2, amide –NH, hydroxyl –OH, or sulfhydryl –SH groups. Depending on the abundance of CEST-expressing metabolites in tissue, the exchange rate, and the frequency offset of their exchanging protons, CEST MRI has been tailored for non-invasive imaging of mobile proteins and peptides with amide groups [1,2,3,4,5], liver glycogen [6], cartilage glycosaminoglycans [7], brain glutamate [8,9,10], myo-inositol [11,12], creatine [13,14,15], as well as other metabolites, with a spatial resolution down to sub-millimeter levels. Proton exchange is the fundamental contrast mechanism in CEST MRI. It also plays an integral role in producing other MR imaging contrasts, including T1- and T2- relaxations, macromolecular magnetization transfer (MT), and exchange-relayed nuclear Overhauser enhancement (NOE) [16].
Despite the importance of proton exchange in various MRI contrasts, in vivo quantification and mapping of kex remains a challenge and has not been achieved until recently [17]. Current methods for kex measurement include MR spectroscopy (MRS), model-based fitting, and exogenous contrast agents. Water exchange (WEX) [18] and the measurement of linewidths [19] are techniques built on MRS which inherently has low resolution and is more suitable for slow exchange rates to avoid signal loss [20]. The method of fitting the Z-spectral to Bloch–McConnell equations for the quantification of kex [21] is highly dependent on the initial estimation of parameters that are not measurable. Similarly, novel fingerprinting-based MRI [22,23] has potential for clinical translation but it also relies on simulated datasets from Bloch-McConnell models. Exogenous contrast-based methods [24] require the injection of chemical agents to compete with the background signal. These methods all require knowing the concentration of the agent that is hard to measure. Quantifying exchange using saturation time and saturation power dependencies [20] and their linearized versions [25,26] offer a more straightforward fitting process for kex measurement.
The Omega plot method [25], initially developed for paramagnetic CEST (paraCEST) experiments [27], on the other hand, provides a direct way for determining kex independent of the CEST agent concentration. In this method, exchange rate values are quantified by fitting the Omega plot, consisting of the inverse of the signal intensity, Mz/(M0−Mz), as a function of 1/ω2 (ω = γB1 refers to the saturation pulse strength). However, for in vivo tissues, the proton exchanging molecules are endogenous diamagnetic CEST (diaCEST) metabolites [28], with resonance frequencies that are close to water. The small offset frequency of the diaCEST agents, typically within 5 ppm [29], means their signal is affected by the neighboring water direct saturation (DS) signal. It has been demonstrated that by considering the water DS effect and removal of its contribution, the Omega plot method improved the kex quantification in solution phantoms [30].
In what follows, we describe the improved Omega plot method, hereafter the DS-removed Omega plot, for in vivo tissue kex mapping. We then review the studies on the validation of the DS-removed Omega plot method and its applications for healthy human subjects and patients with various pathologies. Studies have demonstrated the diagnostic value of MRI-based in vivo kex imaging for assessing lesion activity in neurological diseases such as multiple sclerosis (MS) lesions stratification and monitoring treatment responses in strokes. The findings are suggestive of kex MRI as an invaluable imaging biomarker for oxidative stress and related pathologies once it gets confirmed with parallel biopathological studies.

2. Methods

2.1. Basic Principles

The principle of kex MRI using CEST can be explained in a modeled two-pool exchanging system between pool A (such as bulk water protons) and pool B (solute molecules with exchangeable protons) as follows. Low-concentration solute molecules with exchangeable protons (e.g., amide, amine, hydroxyl protons) are selectively irradiated with radiofrequency (RF) irradiation. Continuous RF irradiation reduces the signal of the solute molecules when the rate of saturation is fast compared to the solute’s inherent relaxation rates (R1 and R2). Due to the proton exchange of the saturation-labeled solute with water protons, the water signal becomes indirectly saturated. Given the low concentration of solute (μM to mM), a single transfer of saturation would be insufficient to show any effect on water protons (~100 M). However, by using a prolonged RF irradiation the saturation of the exchangeable protons in the solute pool can continuously transfer to the water pool by exchanging the saturated protons in the solute pool with the non-saturated protons from the water pool. For the solute protons with a sufficiently fast kex and for sufficiently long relaxation times of water, T1 and T2, continuous RF irradiation (for several seconds) leads to a substantial enhancement of the saturation transfer effect.
The reduction in the signal of the pool B protons due to RF irradiation can be written as
m B = M Z , s s B M Z , e q B   = 1 α
where α is the saturation efficiency. For relatively fast exchange rates compared to T1 and T2 relaxation rates ( k e x R 1   &   R 2 ), the saturation efficiency can be approximated as [20,31,32,33]
α = ω 1 2 ω 1 2 + k e x 2
in which ω 1 = γ B 1 , where B 1 is the applied saturation pulse (RF irradiation) power and γ is the nuclear gyromagnetic ratio (1 µT is equivalent to 42.58 Hz for protons). The rate of signal loss in pool A due to saturation transfer from pool B or the rate of the saturation transfer RST can be determined by considering these factors: the exchange rate between the pools ( k e x ); the fraction of protons in the solute molecule relative to that of water ( f B ); and the signal of pool B protons ( 1 m B ).
R S T = k e x × f B × 1 m B = k e x × f B × α = k e x × f B × ω 1 2 ω 1 2 + k e x 2
Concurrently, the reduced signal of pool A protons (due to the exchange mechanism) recovers back because of the inherent spin-lattice relaxation (T1-recovery) process with the rate of
1 M Z , s s A M Z , e q A R 1 A
where ( R 1 A = 1 / T 1 A ). Under a steady-state condition, the signal loss balances the signal gain in pool A, and the magnitude of the steady-state signal due to the CEST effect can be described by
M Z , s s A M Z , e q A × R S T = M Z , s s A M Z , e q A × k e x × f B × ω 1 2 ω 1 2 + k e x 2 = 1 M Z , s s A M Z , e q A R 1 A  
The kex can be assessed by noting that this relation for the magnetization signal of the water pool can be rewritten as
M Z , s s A M Z , e q A M Z , s s A = R 1 K e x f B 1 k e x 2 + 1 ω 1 2
This relation (the Omega plot relation) indicates the linear dependency of y = M z M e q M z versus x = 1 ω 1 2 . Additionally, the x-intercept of the plot of M z M e q M z as a function of 1 ω 1 2 (the Omega plot) leads to the kex value. Multiplying the Omega plot relation, term by term, by ω 1 2 gives a similar equation
M Z , s s A M Z , e q A M Z , s s A ω 1 2 = R 1 k e x f B ω 1 2 k e x 2 + 1
that can also be used to determine the kex value from the x-intercept of the new plot of y = M z M e q M z ω 1 2 versus x = ω 1 2 due to the linear dependency of y and x . While in either plot the exchange rate can be determined from the x-intercept of the plot, in the second one, the data points contribute to the linear regression with equal weights.
The Omega plot method has been generalized to include multiple proton-exchanging metabolites [17]. It can be shown that in this situation the same relations hold if one considers kex as the convoluted exchanging rates of the multiple exchange sources (n), defined as
k e x 2 = 1 n k s i f i 1 n 1 f i k s i = M 1 k s i f i × M 1 f i k s i = p 2 f i k s i = p 2 k ¯ e x
in which k s i are the exchange rates of the metabolites with water, f s i are the fraction of their protons relative to that of water, and M 1 and M 1 indicate the arithmetic and the harmonic means, respectively.
In practice, in vivo tissue kex is a weighted average exchange rate of all exchanging protons contributing to various MRI contrasts, such as semi-solid MT, CEST, and exchange-relayed NOE [16]. The CEST signal due to amide protons (APT) (around 3.5 ppm downfield from the water resonance) is commonly used as the reference signal for in vivo kex imaging. Many proteins and peptides contain multiple amide protons at about the same frequency offsets with the cumulative proton concentration of about 70 mM, leading to a large composite resonance [34]. In this way, the detection sensitivity of MRI techniques based on APT CEST corresponds to the millimolar concentration of substances in tissue.
In collecting the Z-spectral signal in vivo, DS and conventional semi-solid MT occur along with the CEST effect. The water DS effect is particularly dominant when the saturation offset is close to the water proton resonance. The DS effect can thus contaminate the proton exchange rate quantification using the Omega plot, especially for endogenous diaCEST metabolites. These dominant DS effects need to be separated out. This can be conducted using analytical signal removal, which has been attempted via fitting the flipped Z-spectrum to multiple Lorentzian functions. The schematic of the method is outlined as a flowchart in Figure 1, and the details are described in what follows.

2.2. DS Removing

To extend the Omega plot analysis for the exchangeable protons whose signal is overlapped by the DS water signal, one may mathematically remove the DS signal from the raw CEST signal by analytical methods. Fitting to Lorentzian functions has been used to analyze the Z-spectral signal as a linear combination of multiple components [35]. This method has already been employed in many studies to fit out background signals from DS and MT and to study the remaining CEST-based signals of interest [13,15,36,37].
Given the prominent DS signal in the Z-spectra, one can readily employ fitting the central portion of the Z-spectrum to Lorentzian functions to compensate for the DS contribution. Each Z-spectrum can be fitted to just two Lorentzian functions: a relatively narrow one, which corresponds to DS, and an overly broad one, corresponding to all the residual signals (containing CEST, NOE, and the semi-solid MT). After removing the fitted Lorentzian function corresponding to the DS signal from the total signal, the residue Z-spectrum can be used for constructing the Omega plots and, subsequently, the exchange rate determination.
In this fitting procedure, the Z-spectra within the ±6 ppm range are normalized to the signal at an offset that represents no saturation (>>10 ppm). Z-spectra are then flipped to be 100 × (1 − Mz/M0) and fitted to a sum of two Lorentzian functions: one (centered around 0 ppm) corresponding to the bulk water signal, and the second (centered about −1.5 ppm) to all the remaining effects (mainly MT from semi-solid components, CEST and NOE, together hereafter referred to as the DS-removed Z-spectrum). In this method, the offset of the fitted water DS peak can be estimated as static field B0 map. The kex values can then be calculated using the described Omega plot methods based on a set of DS-removed Z-spectra under varied saturation B1 power. Exchange rate maps can be constructed following this procedure for each pixel.
For fitting the Z-spectra to the Lorentzian function and the DS-removal procedure, one can use MATLAB’s nonlinear constrained routine “lsqcurvefit” iteratively with the fitting function
Z ω = 100 1 2 L n ω
L n ω = A n 1 + 4 ω ω 0 , n l w n 2
where ω is the frequency offset relative to water resonance and A, ω0 and lw are the amplitude, center frequency offset, and the linewidth of each peak, respectively. Their initial values can be chosen in reference to the values listed in [13]. To allow the fitting parameter to vary from these initial parameters the constraints should be loosely chosen. More details are described elsewhere [17]. It is advisable to start the fitting from the Z-spectrum acquired at the lowest saturation power due to narrow linewidths for each component that are more distinguishable. The fitted parameters can then be used as the starting fitting values for the next Z-spectrum at the higher saturation power.
After the fitting, the DS peak is subtracted from the raw Z-spectra, and the remaining signal at particularly offset (such as +3.5 ppm)
M z ω = Z ω L D S ω
is used for the construction of the Omega plot and determining the kex value, as described in the previous section.
Before Z-spectral fitting, one may need to perform motion correction. The motion artifacts due to movements during the data acquisition can be corrected by MATLAB’s intensity-based image registration routine “imregister”. Once a reference image is selected (typically the image collected at a middle offset), the images from each Z-spectrum can be registered to that. Since in each Z-spectrum set the overall intensity of the images changes gradually as the saturation frequency shifts closer to the water resonance, an efficient succession could be that each image gets registered to the image with the adjacent offset, which is assumed to have the most comparable intensity [38].

3. Validation

The Omega plot method technique has already been validated with multiple methods, including direct NMR linewidth fitting, as well as fitting CEST spectra to Bloch equations. The results show that it is possible to quantify the kex for underlying CEST systems at different temperatures and pH levels [25,30,39]. As mentioned in the introduction, for in vivo studies, the overlapping water signal interferes with the signal of the diaCEST metabolites. A DS removal scheme is thus proposed in the DS-corrected Omega plot technique to address this issue. It has been demonstrated that the accuracy of the DS-corrected Omega plot was greatly improved compared to the uncorrected one, using both numerical simulations and experiments on creatine solutions at varying concentrations or pHs [30].
The applicability of the DS-removed Omega plot for kex imaging was also validated using phantoms involving protein solution at varied pH in the physiological range (pH 6.2 to 7.4) as pH is known to change kex [17]. The results show that kex quantified from the DS-removed plots are linearly correlated with the pH values (R2 = 0.998). In comparison, without DS-removing, kex showed a reduced linear dependency on pH with a reduced dynamic range due to pH variations (Figure 2). The water DS signal reduces the overall Z-spectral signal and therefore significantly contributes to kex evaluation based on Omega plots. Therefore, removing DS increases the sensitivity to detecting kex changes, particularly for endogenous metabolites’ exchangeable protons whose resonance offsets are overlapped by the bulk water signal.

4. Applications

The added value of kex MRI in differentiating the affected brain tissues can potentially serve as a surrogate imaging biomarker for the metabolic changes of the tissue. This can aid in the monitoring and assessment of treatment effects as well as guiding therapies, such as radiotherapy, local chemotherapy, and surgery. The DS-removed Omega plot method has been implemented in several studies for in vivo tissue kex quantification and mapping of brains of healthy subjects [17], patients with stroke lesions [40], or MS lesions [41].
kex MR imaging of the human brain usually included the following acquisitions. T2-weighted images were obtained for slice selection. Z-spectral data were then acquired with several saturation powers (B1) in the range of 1 to 5 µT (such as B1 = 1.5, 2.5 and 3.5 µT) with saturation duration of 1.5 or 2 sec, covering a wide range of saturation offsets from −5 to 5 ppm at an increment of 0.25 ppm or less and a reference image at an offset far from water (such as close to 100 ppm or more).

4.1. Mapping the Healthy Human Brain

The applicability of in vivo kex mapping studies was first demonstrated in healthy human brains [17]. Ten healthy volunteers (males and females, 22–25 years old) underwent MRI scanning for the described kex MRI on a 3.0 T scanner with a 32-channel head coil. The kex maps were created using four sets of Z-spectral images acquired with the saturation powers = 1, 2, 3 and 4 µT and saturation duration = 1.5 s on a single slice from the middle brain parallel to the anterior commissure–posterior commissure (AC-PC) line. The quantified kex with the DS-removed Omega plot showed significantly higher values in the gray matter (GM) region than in the white matter (WM) region (616 ± 29 vs. 575 ± 20 s−1, p < 0.001) [17].
The higher exchange rate observed in the GM compared to the WM is most likely the result of differences in their metabolites. This is because the other factors influencing the exchange rate, such as pH and temperature, are not expected to differ significantly. In general, GM has greater metabolic activity than WM. This means it may contain higher levels of metabolites with relatively high exchange rates compared to WM. This study indicates that the in vivo kex method can reliably detect variations in the metabolite profile when there is no significant variation in pH and temperature.
One should note that the calculated exchange rate in tissue is in general a weighted average of all saturation transfer exchanging proton species that contribute to the Z-spectral signal. In vivo, there are many endogenous metabolites, which undergo many saturation transfers and proton exchanges at different offset frequencies and different exchange rates with broad and overlapping peaks. The downfield side of the Z-spectrum has contributions from various saturation transfer sources, including semi-solid macromolecules (the MT effect) and various exchangeable labile proton species present in vivo. Furthermore, metabolites have different kex and each gets optimally saturated under a different saturation power. These considerations and the fact that Omega plots require a set of saturation powers indicate that the quantified kex in tissue is a weighted average of all contributing metabolites’ kex from all proton-exchanging mechanisms.

4.2. Detecting the Metabolic Disturbance of Ischemic Stroke Tissues

In vivo kex MRI based on the improved Omega plot has been implemented to map the brains of ischemic stroke patients [40]. In a study of 23 patients with ischemic stroke, kex MRI maps were constructed using three sets of Z-spectra (B1 = 1.5, 2.5 and 3.5 µT) and saturation duration = 1.5 s, along with the other conventional contrast, including diffusion-weighted imaging (DWI), CEST, and semi-solid MT MRI. The derived kex maps differentiated infarcts from the contralateral normal brain tissues with significantly increased kex (893 ± 52 s−1 vs. 739 ± 34 s−1, p < 0.001). The kex maps were also found to differ from the conventional contrast MRIs. In the kex maps, the infarct lesions displayed considerably larger areas than that delineated in DWI (3.69–297%, mean and standard deviation 43.6 ± 67.7%, p < 0.05) for all cases (Figure 3). In addition, the kex maps also showed different lesion contrast compared to CEST and MT.
In stroke clinics, the definition of ischemic penumbra is useful in the decision for recanalization therapy. The observed mismatch between kex and DWI maps suggests that kex MRI may serve as a novel and independent MRI contrast for assessing affected brain tissues in stroke patients and defining ischemic penumbra. Ongoing investigations with longitudinal and histological studies will validate this concept.

4.3. Detecting and Grading MS Lesions

The described method of in vivo kex MRI has been performed for MS patients and its potential value for staging clinical MS lesions has been evaluated [41]. MS is an autoimmune neurodegenerative disease that is a leading cause of neurologic disability in young adults. It involves the chronic inflammation of the central nervous system, characterized by lesions in multiple tissues, especially in demyelination of the white matter that may later progress to axonal damage. The diagnosis of MS is currently based on the McDonald criteria [42], in which MRI is an essential part.
MS lesions can be classified into five pathological stages: early active, late active, smoldering, inactive, and shadow plaques [43]. The ability to risk-stratify MS lesion activity would help predict prognosis and guide treatment. As part of this effort, PET tracers are being developed and tested for imaging demyelination and inflammation in MS [44], including MeDAS [45] for myelination, Pittsburgh compound B (PiB) [46] for amyloid, translocator protein 18 (TSPO) [47] for neuroinflammation. However, each tracer has different binding specificity and half-life and the use of PET in MS even in the research setting is still in its infancy [44]. MRI methods do not use ionizing radiation and can be easily incorporated into clinical protocols. With considerable sensitivity [48,49], conventional T1w&T2w MRI methods detect MS lesions as hypointense black holes (axonal loss) [50] and with hyperintensity (edema or demyelination) [51], respectively. Through the measurement of blood–brain barrier breakdown, Gd-enhanced MRI is commonly employed to discern different stages of the lesions in an MS patient. Gadolinium (Gd) enhancement on postcontrast T1-weighted images (T1WI), signals blood–brain barrier disruption and active inflammation [43].
Gd enhancement in MS lesions, however, has a narrow time window, so underestimating the lesion’s activity is common. Individual new lesions show the average duration of Gd enhancement in about 3 weeks [52], and the vast majority of Gd enhancements disappear within 6 months [53]. Later, when MS lesions turn into non-enhanced lesions, their stages cannot be identified. It has been known that after Gd-enhancement resolves, inflammation persists in some lesions [54,55,56]. These non-enhancing lesions can be categorized according to the presence or absence of ongoing inflammation into chronic active lesions (slowly expanding lesions) and chronic inactive lesions [56,57,58]. As a result, the activity of the lesions is often underestimated with only Gd-enhanced MRI evaluations. This makes developing further MRI biomarkers to improve the characterization of MS lesions highly desirable. There are several emerging MRI methods being investigated for MS studies, including diffusion tensor or kurtosis imaging for changes in water diffusion in myelin [59,60,61], multicomponent T2 mapping [62,63,64], and ultrashort or zero echo time (UTE) MRI [65,66] for myelin water, and quantitative susceptibility mapping (QSM) [67] sensitive to iron deposition.
Sensitive to the myelin lipid content, MT MRI [68,69] has been used as an MR method to detect demyelination in MS [70,71]. Additionally, metabolic changes used as early biomarkers of MS have been evaluated with proton MRS [72,73,74], however, with limited sensitivity [75]. Molecular CEST MRI, on the other hand, produces high-resolution metabolite maps with hundreds to thousands of times amplified sensitivity compared to MRS [75]. This includes the described DS-removed Omega plot method for kex mapping.
In vivo kex MRI was implemented in MS in this regard. Brain kex MRI in MS patients was performed with the described DS-removed Omega plot method and showed a high correlation to Gd-enhanced images, with increased kex signal in all the Gd-enhanced lesions [41]. In this study, 16 MS-diagnosed subjects (7 male, 9 female) underwent a brain MRI on a 3 T clinical scanner. In vivo kex maps were generated by the DS-removed Omega plot constructed from five different saturation powers (B1 = 1, 2, 3, 4 and 5 µT) and saturation duration = 1.5 s. Of all 153 MS lesions, 78 (51%) lesions were Gd-enhancing and 75 (49%) were Gd-negative. All 78 Gd-enhancing lesions showed significantly elevated kex values compared to normal-appearing white matter (NAWM) (924  ±  130 s–1 vs. 735  ±  61 s–1, p  <  0.05). For the 75 Gd-negative lesions, 18 lesions (24%) showed no kex elevation (762  ±  29 s–1 vs. 755  ±  28 s–1, p = 0.47) and 57 (76%) showed significant kex elevation (950  ±  124 s–1 vs. 759  ±  48 s–1, p  <  0.05) compared to NAWM (Figure 4).
These initial findings on kex MRI of MS lesions suggest the unique potential of kex MRI as a valuable imaging biomarker for characterizing MS lesion activity of Gd-negative lesions. Generally, Gd-enhanced MRI shows limited correlation with clinical disability [76]. It has been shown that some recently developed and most chronic MS lesions are Gd-negative [52,53]. In addition, gadolinium administration has complications [77] with potential brain accumulation [78]. The results suggest that kex mapping may be useful in separating slowly expanding MS lesions (chronic active lesions) from inactive ones. Hence, as an endogenous MRI contrast, kex MRI could be an alternative technique to the positron emission tomography (PET) with 11C-(R)-PK11195 (targeting activated microglia or macrophages) [44] or susceptibility weighted imaging (SWI, targeting abnormal iron deposition) [79] that have been proposed for differentiation of non-enhancing MS lesions.

5. Discussion

We reviewed the studies demonstrating the feasibility of mapping the proton exchange rate in vivo with Omega plots using DS-removed Z-spectral signals. RF irradiation is used to implement saturation in this CEST MR imaging technique, which is then transferred to the water protons via the ubiquitous proton exchange. The drop in the water signal due to this transfer of the saturation is detected and the physical parameters get inferred from the transferred saturation. Indeed, the name of the process, i.e., chemical exchange saturation transfer (CEST), clearly described the basics of the technique, which is based on the saturation that is transferred via the chemical exchange process. The basic principle of the CEST technique has been described in several excellent reviews published in recent years [29,33,80,81]. In short, the contrast mechanism in CEST imaging involves the irradiation of RF radiation to produce saturation. As a result of the saturation transfer, MR imaging contrast is produced which enables quantification of exchange-related parameters. Proton exchange is a physical phenomenon that is constantly happening between exchangeable protons in the metabolites and the water protons regardless of whether the saturation RF is “no” or “off”.
In kex MRI, the contrast is generated primarily from the kex of the endogenous metabolites in the tissue. As a physical parameter, in vivo kex may reflect variation in the pH, temperature, reactive oxygen species (ROS) activity, or the profile of tissue metabolites containing slow or fast exchangeable protons [82]. To explain the kex variations in the in vivo studies, one needs to discern the factors which can explain the observed kex variation.
In the ischemic stroke tissues, kex MRI mapping presented a larger area of the infarct lesions in the kex maps compared to in the DWI maps [40]. This disparity reflects the distinctive contrast mechanism of kex imaging as compared to conventional MRI. The observed increased kex in the infarct lesions due to ischemic stroke cannot be attributed to factors such as increased pH, temperature, or metabolite changes. It has been shown that following an ischemic stroke, enhanced anaerobic metabolism leads to tissue acidosis and hence a pH reduction in the damaged tissues [83], which would be reflected as a decrease in the kex value. Furthermore, the brain temperature is normally well controlled and its variation in the ischemic brain is reported to be within 1 °C [84]. Additionally, it has been shown that during the initial stage of the stroke (<24 h), some minor amino acids with generally higher exchanging protons show an elevation in the tissue [85,86,87]. This, however, should have already subsided since the majority of small metabolites with generally higher exchanging protons are reported to decrease after 24 h [88,89]. This reduction in small metabolites with a relatively faster proton exchange rate compared to macromolecules should result in a reduction in the tissue kex.
The elevated kex observed in ischemic tissues should be attributed to other factors. Recent studies have shown that the production of ROS can increase the kex of tissue metabolites [82,90,91]. During cerebral ischemia, an imbalance occurs between the production of ROS and the antioxidant capacity. This results in excessive ROS production that directly or indirectly contributes to oxidative damage and eventually cellular damage and death [92]. Thus, the pronounced increase in kex in the infarct region could be due to elevated ROS production. The hypothesis, however, needs to be further investigated via invasive measurements of tissue ROS in experimental animal models.
Similarly, the observed increases in kex values in the MS lesions [41] are suggested to be the result of ROS overproduction and elevated oxidative stress associated with MS pathogenesis [93]. With the potential for targeting ROS [82,90], kex MRI may further characterize Gd-negative lesions based on lesion activity. Additional validation is necessary with pathological studies on preclinical MS models.

6. Challenges and Opportunities

There are several challenges associated with the described Omega plot-based kex imaging, some of which are similar to those associated with other conventional Z-spectrum-based imaging. These techniques in general require a long saturation time to fulfill the steady-state assumption [25], which in theory calls for RF irradiation for as long as ≥ 10 s, potentially leading to a high specific absorption rate (SAR) exposure. To avoid the potential risk of high SAR or RF heat deposition due to the prolonged scanning times, in the clinical settings, the steady-state saturation required by the Omega plot was approximated with a 1–2 seconds-long saturation pulse or pulse train. According to simulations with Bloch-McConnell equations, applying 1.5 s of saturation can result in ~65% of the steady-state saturation when B1 = 1 µT and 99% of the steady-state value when B1 = 4 µT, for the kex values in the 30–3000 s−1 range [17].
Another issue is the length of the scanning. The described Omega plot-based kex imaging requires multiple Z-spectral acquisitions, which increases the total scanning time. Given the linearity of the Omega plot, the scanning time may be reduced by acquiring two Z-spectra. This has been shown in the healthy brain study that the kex maps constructed with only two Z-spectra showed very similar values to those calculated using 4 Z-spectra [17]. The scanning time may be further reduced by decreasing the number of offsets in the Z-spectrum and by implementing fast-reading pulse sequences.
In the described kex imaging based on the DS-removed Omega plot, we do not expect artifacts due to the inhomogeneity of B0 since the fitting process automatically corrects B0 variations. Having a homogeneous B1 field over the field of view (FOV), however, is an instrumental factor in producing an accurate kex map. The determination of kex is based on the X-intercept of the Omega plot, which depends on the B1 values of the RF saturation pulse. Inhomogeneity of B1 field strength can directly affect the Omega plot intercept and accordingly the kex. Therefore, aiming for a homogenous applied RF pulse over the field of view has a significant role in an accurate evaluation of the kex variation. Otherwise, B1 correction is necessary by acquiring a B1 map [8] and using corrected B1 values for constructing Omega plots.
Another potentially challenging issue for the kex MRI based on the DS-removed Omega plot is the quantification of the DS signal. The Lorentzian fitting of the DS spectrum may not always be sufficiently accurate particularly when saturation power is high and under low field strength. It is still needed to study the interaction of DS with the proton-exchanging mechanisms that are close to water resonance to improve the DS quantification.
In the above-reviewed in vivo kex MRI studies, the implementation of the DS-removed Omega plot was done at clinical 3 T scanners. The DS-removed Z-spectra contain a large contribution from MT due to semi-solid macromolecules, which can contribute to the calculated kex. Furthermore, at 3 T field strength, the individual CEST-expressing metabolites have broad and overlapping peaks in the Z-spectrum. Therefore, the calculated kex in tissue is a weighted average from the various saturation transfer sources, including semi-solid MT associated with macromolecules and CEST effects from various mobile proteins, peptides, and small metabolites. The described method for determining kex, however, can be improved by using the Z-spectra collected at higher field strengths. With the better resolved Z-spectra at higher fields (such as at 7 T or 9.4 T), Z-spectral fitting can be utilized to separately quantify individual proton-exchanging mechanisms [13,37,94,95], such as semi-solid MT, creatine CEST at 2 ppm, APT, and relayed NOE, etc. Using the signal of each exchangeable proton group, the Omega plot can be constructed accordingly for determining kex more specifically for each proton-exchanging component.

7. Conclusions

The Omega plot method is known as a direct MR method for determining kex independent of the CEST agent concentration. However, the use of this method is limited to in vitro studies and paramagnetic CEST experiments. This method can be improved by removing the obtrusive water DS contribution from the MR signal and can be applied for in vivo studies involving diaCEST metabolites. kex MRI based on the DS-removed Omega plot is an emerging technique for mapping the proton exchange rate of tissue metabolites in vivo. Proton exchange is an invaluable biophysical parameter that can reflect variations in the imaging milieu due to factors such as metabolite changes, pH, temperature, and ROS overproduction. In this MRI technique, the contrast is generated by endogenous metabolite species with exchangeable protons. Therefore, it does not require exogenous contrast agent injection.
The technique has shown promise for several practical applications, including but not limited to, imaging of ischemic stroke and MS brain. In studies of brain lesions due to ischemic stroke, kex MRI presented an improved definition of ischemic penumbra. The published data from clinical MS patients demonstrated that kex MRI further differentiates the Gd-negative lesions into kex positive and negative groups. These findings suggest the diagnostic value of kex MRI for assessing the lesion activity and its potential in enhancing the sensitivity and specificity for lesion stratification, as well as monitoring treatment responses. It was suggested that increased proton exchange promoted by ROS overproduction could be a major contribution to the tissue kex elevation. kex MRI therefore might be a valuable imaging biomarker for oxidative stress and related pathologies. Once validated with further biopathological studies, in vivo kex imaging will have broad clinical applications for the diagnosis and treatment of neurological diseases.

Funding

There is no funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Zhou, J.Y.; Tryggestad, E.; Wen, Z.B.; Lal, B.; Zhou, T.T.; Grossman, R.; Wang, S.L.; Yan, K.; Fu, D.X.; Ford, E.; et al. Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat. Med. 2011, 17, 130–308. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Dula, A.N.; Asche, E.M.; Landman, B.A.; Welch, E.B.; Pawate, S.; Sriram, S.; Gore, J.C.; Smith, S.A. Development of chemical exchange saturation transfer at 7 T. Magn. Reson. Med. 2011, 66, 831–838. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Dula, A.N.; Smith, S.A.; Gore, J.C. Application of chemical exchange saturation transfer (CEST) MRI for endogenous contrast at 7 Tesla. J. Neuroimaging 2013, 23, 526–532. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. By, S.; Barry, R.L.; Smith, A.K.; Lyttle, B.D.; Box, B.A.; Bagnato, F.R.; Pawate, S.; Smith, S.A. Amide proton transfer CEST of the cervical spinal cord in multiple sclerosis patients at 3T. Magn. Reson. Med. 2018, 79, 806–814. [Google Scholar] [CrossRef]
  5. Sartoretti, E.; Sartoretti, T.; Wyss, M.; Becker, A.S.; Schwenk, A.; van Smoorenburg, L.; Najafi, A.; Binkert, C.; Thoeny, H.C.; Zhou, J.; et al. Amide Proton Transfer Weighted Imaging Shows Differences in Multiple Sclerosis Lesions and White Matter Hyperintensities of Presumed Vascular Origin. Front. Neurol. 2019, 10, 1307. [Google Scholar] [CrossRef]
  6. van Zijl, P.C.; Jones, C.K.; Ren, J.; Malloy, C.R.; Sherry, A.D. MRI detection of glycogen in vivo by using chemical exchange saturation transfer imaging (glycoCEST). Proc. Natl. Acad. Sci. USA 2007, 104, 4359–4364. [Google Scholar] [CrossRef] [Green Version]
  7. Ling, W.; Regatte, R.R.; Navon, G.; Jerschow, A. Assessment of glycosaminoglycan concentration in vivo by chemical exchange-dependent saturation transfer (gagCEST). Proc. Natl. Acad. Sci. USA 2008, 105, 2266–2270. [Google Scholar] [CrossRef] [Green Version]
  8. Cai, K.; Haris, M.; Singh, A.; Kogan, F.; Greenberg, J.H.; Hariharan, H.; Detre, J.A.; Reddy, R. Magnetic resonance imaging of glutamate. Nat. Med. 2012, 18, 302–306. [Google Scholar] [CrossRef] [Green Version]
  9. Haris, M.; Nath, K.; Cai, K.; Singh, A.; Crescenzi, R.; Kogan, F.; Verma, G.; Reddy, S.; Hariharan, H.; Melhem, E.R.; et al. Imaging of glutamate neurotransmitter alterations in Alzheimer’s disease. NMR. Biomed. 2013, 26, 386–391. [Google Scholar] [CrossRef] [Green Version]
  10. Cai, K.; Singh, A.; Roalf, D.R.; Nanga, R.P.; Haris, M.; Hariharan, H.; Gur, R.; Reddy, R. Mapping glutamate in subcortical brain structures using high-resolution GluCEST MRI. NMR. Biomed. 2013, 26, 1278–1284. [Google Scholar] [CrossRef] [Green Version]
  11. Haris, M.; Cai, K.; Singh, A.; Hariharan, H.; Reddy, R. In vivo mapping of brain myo-inositol. Neuroimage 2011, 54, 2079–2085. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Haris, M.; Singh, A.; Cai, K.; Nath, K.; Crescenzi, R.; Kogan, F.; Hariharan, H.; Reddy, R. MICEST: A potential tool for non-invasive detection of molecular changes in Alzheimer’s disease. J. Neurosci. Methods 2013, 212, 87–93. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Cai, K.; Singh, A.; Poptani, H.; Li, W.; Yang, S.; Lu, Y.; Hariharan, H.; Zhou, X.J.; Reddy, R. CEST signal at 2ppm (CEST@2ppm) from Z-spectral fitting correlates with creatine distribution in brain tumor. NMR. Biomed. 2015, 28, 1–8. [Google Scholar] [CrossRef] [Green Version]
  14. Chen, L.; Zeng, H.; Xu, X.; Yadav, N.N.; Cai, S.; Puts, N.A.; Barker, P.B.; Li, T.; Weiss, R.G.; van Zijl, P.C.M.; et al. Investigation of the contribution of total creatine to the CEST Z-spectrum of brain using a knockout mouse model. NMR. Biomed. 2017, 30, e3834. [Google Scholar] [CrossRef]
  15. Singh, A.; Debnath, A.; Cai, K.; Bagga, P.; Haris, M.; Hariharan, H.; Reddy, R. Evaluating the feasibility of creatine-weighted CEST MRI in human brain at 7 T using a Z-spectral fitting approach. NMR. Biomed. 2019, 32, e4176. [Google Scholar] [CrossRef] [PubMed]
  16. Jones, C.K.; Huang, A.; Xu, J.; Edden, R.A.E.; Schar, M.; Hua, J.; Oskolkov, N.; Zaca, D.; Zhou, J.; McMahon, M.T.; et al. Nuclear Overhauser enhancement (NOE) imaging in the human brain at 7T. Neuroimage 2013, 77, 114–124. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Shaghaghi, M.; Chen, W.; Scotti, A.; Ye, H.; Zhang, Y.; Zhu, W.; Cai, K. In vivo quantification of proton exchange rate in healthy human brains with omega plot. Quant. Imaging. Med. Surg. 2019, 9, 1686–1696. [Google Scholar] [CrossRef]
  18. Mori, S.; Abeygunawardana, C.; van Zijl, P.C.; Berg, J.M. Water exchange filter with improved sensitivity (WEX II) to study solvent-exchangeable protons. Application to the consensus zinc finger peptide CP-1. J. Magn. Reson. B. 1996, 110, 96–101. [Google Scholar] [CrossRef]
  19. Haris, M.; Nanga, R.P.; Singh, A.; Cai, K.; Kogan, F.; Hariharan, H.; Reddy, R. Exchange rates of creatine kinase metabolites: Feasibility of imaging creatine by chemical exchange saturation transfer MRI. NMR. Biomed. 2012, 25, 1305–1309. [Google Scholar] [CrossRef]
  20. McMahon, M.T.; Gilad, A.A.; Zhou, J.; Sun, P.Z.; Bulte, J.W.; van Zijl, P.C. Quantifying exchange rates in chemical exchange saturation transfer agents using the saturation time and saturation power dependencies of the magnetization transfer effect on the magnetic resonance imaging signal (QUEST and QUESP): Ph calibration for poly-L-lysine and a starburst dendrimer. Magn. Reson. Med. 2006, 55, 836–847. [Google Scholar] [CrossRef] [Green Version]
  21. Woessner, D.E.; Zhang, S.; Merritt, M.E.; Sherry, A.D. Numerical solution of the Bloch equations provides insights into the optimum design of PARACEST agents for MRI. Magn. Reson. Med. 2005, 53, 790–799. [Google Scholar] [CrossRef] [PubMed]
  22. Zhou, Z.; Han, P.; Zhou, B.; Christodoulou, A.G.; Shaw, J.L.; Deng, Z.; Li, D. Chemical exchange saturation transfer fingerprinting for exchange rate quantification. Magn. Reson. Med. 2018, 80, 1352–1363. [Google Scholar] [CrossRef]
  23. Heo, H.Y.; Han, Z.; Jiang, S.; Schar, M.; van Zijl, P.C.M.; Zhou, J. Quantifying amide proton exchange rate and concentration in chemical exchange saturation transfer imaging of the human brain. Neuroimage 2019, 189, 202–213. [Google Scholar] [CrossRef]
  24. Chen, L.Q.; Howison, C.M.; Jeffery, J.J.; Robey, I.F.; Kuo, P.H.; Pagel, M.D. Evaluations of extracellular pH within in vivo tumors using acidoCEST MRI. Magn. Reson. Med. 2014, 72, 1408–1417. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Dixon, W.T.; Ren, J.; Lubag, A.J.; Ratnakar, J.; Vinogradov, E.; Hancu, I.; Lenkinski, R.E.; Sherry, A.D. A concentration-independent method to measure exchange rates in PARACEST agents. Magn. Reson. Med. 2010, 63, 625–632. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Randtke, E.A.; Chen, L.Q.; Pagel, M.D. The reciprocal linear QUEST analysis method facilitates the measurements of chemical exchange rates with CEST MRI. Contrast. Media. Mol. Imaging 2014, 9, 252–258. [Google Scholar] [CrossRef] [Green Version]
  27. Zhang, S.; Merritt, M.; Woessner, D.E.; Lenkinski, R.E.; Sherry, A.D. PARACEST agents: Modulating MRI contrast via water proton exchange. Acc. Chem. Res. 2003, 36, 783–790. [Google Scholar] [CrossRef]
  28. McMahon, M.T.; Gilad, A.A.; DeLiso, M.A.; Cromer Berman, S.M.; Bulte, J.W.; van Zijl, P.C. New “multicolor” polypeptide diamagnetic chemical exchange saturation transfer (DIACEST) contrast agents for MRI. Magn. Reson. Med. Off. J. Int. Soc. Magn. Reson. Med. 2008, 60, 803–812. [Google Scholar] [CrossRef] [Green Version]
  29. Vinogradov, E.; Sherry, A.D.; Lenkinski, R.E. CEST: From basic principles to applications, challenges and opportunities. J. Magn. Reson. 2013, 229, 155–172. [Google Scholar] [CrossRef] [Green Version]
  30. Sun, P.Z.; Wang, Y.; Dai, Z.; Xiao, G.; Wu, R. Quantitative chemical exchange saturation transfer (qCEST) MRI--RF spillover effect-corrected omega plot for simultaneous determination of labile proton fraction ratio and exchange rate. Contrast. Media. Mol. Imaging 2014, 9, 268–275. [Google Scholar] [CrossRef]
  31. van Zijl, P.C.M.; Yadav, N.N. Chemical exchange saturation transfer (CEST): What is in a name and what isn’t? Magn. Reson. Med. 2011, 65, 927–948. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Zhou, J.; Wilson, D.A.; Sun, P.Z.; Klaus, J.A.; Van Zijl, P.C.M. Quantitative description of proton exchange processes between water and endogenous and exogenous agents for WEX, CEST, and APT experiments. Magn. Reson. Med. 2004, 51, 945–952. [Google Scholar] [CrossRef] [PubMed]
  33. Snoussi, K.; Bulte, J.W.M.; Gueron, M.; van Zijl, P.C.M. Sensitive CEST agents based on nucleic acid imino proton exchange: Detection of poly(rU) and of a dendrimer-poly(rU) model for nucleic acid delivery and pharmacology. Magn. Reson. Med. 2003, 49, 998–1005. [Google Scholar] [CrossRef] [PubMed]
  34. Zhou, J.Y.; Payen, J.F.; Wilson, D.A.; Traystman, R.J.; van Zijl, P.C.M. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat. Med. 2003, 9, 1085–1090. [Google Scholar] [CrossRef]
  35. Zaiss, M.S.B.; Stieltjes, B.; Bachert, P. Enhancement of MT and CEST contrast via Heuristic fitting of Z-spectra. In Proceedings of the 20th Annual Meeting ISMRM, Melbourne, Australia, 6 May 2012; p. 5136. [Google Scholar]
  36. Desmond, K.L.; Moosvi, F.; Stanisz, G.J. Mapping of Amide, Amine, and Aliphatic Peaks in the CEST Spectra of Murine Xenografts at 7 T. Magn. Reson. Med. 2014, 71, 1841–1853. [Google Scholar] [CrossRef]
  37. Cai, K.; Tain, R.-W.; Zhou, X.J.; Damen, F.C.; Scotti, A.M.; Hariharan, H.; Poptani, H.; Reddy, R. Creatine CEST MRI for differentiating gliomas with different degrees of aggressiveness. Mol. Imaging Biol. 2017, 19, 225–232. [Google Scholar] [CrossRef] [Green Version]
  38. Bie, C.Y.L.; Chen, Y.; Zhang, L.; Song, X.; He, X. Progressive Registration for Dynamic Salicylate Enhancement (DSE) Image in Chemical Exchange Saturation Transfer (CEST) MRI. In Proceedings of the 7th International Workshop on Chemical Exchange Saturation Transfer (CEST) Imaging, Beijing, China, 7–10 August 2022. [Google Scholar]
  39. Wu, R.; Xiao, G.; Zhou, I.Y.; Ran, C.; Sun, P.Z. Quantitative chemical exchange saturation transfer (qCEST) MRI–omega plot analysis of RF-spillover-corrected inverse CEST ratio asymmetry for simultaneous determination of labile proton ratio and exchange rate. NMR. Biomed. 2015, 28, 376–383. [Google Scholar] [CrossRef] [Green Version]
  40. Wang, Z.; Shaghaghi, M.; Zhang, S.; Zhang, G.; Zhou, Y.; Wu, D.; Zhang, Z.; Zhu, W.; Cai, K. Novel proton exchange rate MRI presents unique contrast in brains of ischemic stroke patients. J. Neurosci. Methods. 2020, 346, 108926. [Google Scholar] [CrossRef]
  41. Ye, H.; Shaghaghi, M.; Chen, Q.; Zhang, Y.; Lutz, S.E.; Chen, W.; Cai, K. In Vivo Proton Exchange Rate (kex) MRI for the Characterization of Multiple Sclerosis Lesions in Patients. J. Magn. Reson. Imaging 2020, 53, 408–415. [Google Scholar] [CrossRef]
  42. Thompson, A.J.; Banwell, B.L.; Barkhof, F.; Carroll, W.M.; Coetzee, T.; Comi, G.; Correale, J.; Fazekas, F.; Filippi, M.; Freedman, M.S. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet. Neurol. 2018, 17, 162–173. [Google Scholar] [CrossRef]
  43. Frischer, J.M.; Weigand, S.D.; Guo, Y.; Kale, N.; Parisi, J.E.; Pirko, I.; Mandrekar, J.; Bramow, S.; Metz, I.; Brück, W. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann. Neurol. 2015, 78, 710–721. [Google Scholar] [CrossRef] [Green Version]
  44. Bauckneht, M.; Capitanio, S.; Raffa, S.; Roccatagliata, L.; Pardini, M.; Lapucci, C.; Marini, C.; Sambuceti, G.; Inglese, M.; Gallo, P.; et al. Molecular imaging of multiple sclerosis: From the clinical demand to novel radiotracers. EJNMMI. Radiopharm. Chem. 2019, 4, 6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Wu, C.; Wang, C.; Popescu, D.C.; Zhu, W.; Somoza, E.A.; Zhu, J.; Condie, A.G.; Flask, C.A.; Miller, R.H.; Macklin, W.; et al. A novel PET marker for in vivo quantification of myelination. Bioorg. Med. Chem. 2010, 18, 8592–8599. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Bodini, B.; Veronese, M.; Garcia-Lorenzo, D.; Battaglini, M.; Poirion, E.; Chardain, A.; Freeman, L.; Louapre, C.; Tchikviladze, M.; Papeix, C.; et al. Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis. Ann. Neurol. 2016, 79, 726–738. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Vomacka, L.; Albert, N.L.; Lindner, S.; Unterrainer, M.; Mahler, C.; Brendel, M.; Ermoschkin, L.; Gosewisch, A.; Brunegraf, A.; Buckley, C.; et al. TSPO imaging using the novel PET ligand [(18)F]GE-180: Quantification approaches in patients with multiple sclerosis. EJNMMI. Res. 2017, 7, 89. [Google Scholar] [CrossRef] [Green Version]
  48. Dalton, C.M.; Brex, P.A.; Miszkiel, K.A.; Fernando, K.; MacManus, D.G.; Plant, G.T.; Thompson, A.J.; Miller, D.H. New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann. Neurol. 2003, 53, 673–676. [Google Scholar] [CrossRef]
  49. McDonald, W.I.; Compston, A.; Edan, G.; Goodkin, D.; Hartung, H.P.; Lublin, F.D.; McFarland, H.F.; Paty, D.W.; Polman, C.H.; Reingold, S.C.; et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50, 121–127. [Google Scholar] [CrossRef]
  50. Bagnato, F.; Jeffries, N.; Richert, N.D.; Stone, R.D.; Ohayon, J.M.; McFarland, H.F.; Frank, J.A. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain. 2003, 126, 1782–1789. [Google Scholar] [CrossRef] [Green Version]
  51. Kearney, H.; Miller, D.H.; Ciccarelli, O. Spinal cord MRI in multiple sclerosis--diagnostic, prognostic and clinical value. Nat. Rev. Neurol. 2015, 11, 327–338. [Google Scholar] [CrossRef]
  52. Cotton, F.; Weiner, H.L.; Jolesz, F.A.; Guttmann, C.R. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003, 60, 640–646. [Google Scholar] [CrossRef]
  53. He, J.; Grossman, R.I.; Ge, Y.; Mannon, L.J. Enhancing patterns in multiple sclerosis: Evolution and persistence. AJNR. Am. J. Neuroradiol. 2001, 22, 664–669. [Google Scholar] [PubMed]
  54. Kaunzner, U.W.; Kang, Y.; Zhang, S.; Morris, E.; Yao, Y.; Pandya, S.; Hurtado Rua, S.M.; Park, C.; Gillen, K.M.; Nguyen, T.D.; et al. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain. A. J. Neurol. 2019, 142, 133–145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Elliott, C.; Belachew, S.; Wolinsky, J.S.; Hauser, S.L.; Kappos, L.; Barkhof, F.; Bernasconi, C.; Fecker, J.; Model, F.; Wei, W.; et al. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain. A. J. Neurol. 2019, 142, 2787–2799. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Elliott, C.; Wolinsky, J.S.; Hauser, S.L.; Kappos, L.; Barkhof, F.; Bernasconi, C.; Wei, W.; Belachew, S.; Arnold, D.L. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Mult. Scler. 2018, 25, 1915–1925. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Matthews, P.M. Chronic inflammation in multiple sclerosis—Seeing what was always there. Nat. Rev. Neurol. 2019, 15, 582–593. [Google Scholar] [CrossRef]
  58. Tommasin, S.; Giannì, C.; De Giglio, L.; Pantano, P. Neuroimaging techniques to assess inflammation in multiple sclerosis. Neuroscience 2019, 403, 4–16. [Google Scholar] [CrossRef]
  59. Gulani, V.; Webb, A.G.; Duncan, I.D.; Lauterbur, P.C. Apparent diffusion tensor measurements in myelin-deficient rat spinal cords. Magn. Reson. Med. 2001, 45, 191–195. [Google Scholar] [CrossRef]
  60. Klawiter, E.C.; Schmidt, R.E.; Trinkaus, K.; Liang, H.F.; Budde, M.D.; Naismith, R.T.; Song, S.K.; Cross, A.H.; Benzinger, T.L. Radial diffusivity predicts demyelination in ex vivo multiple sclerosis spinal cords. Neuroimage 2011, 55, 1454–1460. [Google Scholar] [CrossRef] [Green Version]
  61. Valsasina, P.; Rocca, M.A.; Agosta, F.; Benedetti, B.; Horsfield, M.A.; Gallo, A.; Rovaris, M.; Comi, G.; Filippi, M. Mean diffusivity and fractional anisotropy histogram analysis of the cervical cord in MS patients. Neuroimage 2005, 26, 822–828. [Google Scholar] [CrossRef]
  62. MacKay, A.; Whittall, K.; Adler, J.; Li, D.; Paty, D.; Graeb, D. In vivo visualization of myelin water in brain by magnetic resonance. Magn. Reson. Med. 1994, 31, 673–677. [Google Scholar] [CrossRef]
  63. Horch, R.A.; Gore, J.C.; Does, M.D. Origins of the ultrashort-T2 1H NMR signals in myelinated nerve: A direct measure of myelin content? Magn. Reson. Med. 2011, 66, 24–31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Laule, C.; Leung, E.; Lis, D.K.; Traboulsee, A.L.; Paty, D.W.; MacKay, A.L.; Moore, G.R. Myelin water imaging in multiple sclerosis: Quantitative correlations with histopathology. Mult. Scler. 2006, 12, 747–753. [Google Scholar] [CrossRef]
  65. Sheth, V.; Shao, H.; Chen, J.; Vandenberg, S.; Corey-Bloom, J.; Bydder, G.M.; Du, J. Magnetic resonance imaging of myelin using ultrashort Echo time (UTE) pulse sequences: Phantom, specimen, volunteer and multiple sclerosis patient studies. Neuroimage 2016, 136, 37–44. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Weiger, M.; Froidevaux, R.; Baadsvik, E.L.; Brunner, D.O.; Rosler, M.B.; Pruessmann, K.P. Advances in MRI of the myelin bilayer. Neuroimage 2020, 217, 116888. [Google Scholar] [CrossRef] [PubMed]
  67. Wisnieff, C.; Ramanan, S.; Olesik, J.; Gauthier, S.; Wang, Y.; Pitt, D. Quantitative susceptibility mapping (QSM) of white matter multiple sclerosis lesions: Interpreting positive susceptibility and the presence of iron. Magn. Reson. Med. 2015, 74, 564–570. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Fernando, K.T.; Tozer, D.J.; Miszkiel, K.A.; Gordon, R.M.; Swanton, J.K.; Dalton, C.M.; Barker, G.J.; Plant, G.T.; Thompson, A.J.; Miller, D.H. Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2005, 128, 2911–2925. [Google Scholar] [CrossRef] [PubMed]
  69. Schmierer, K.; Scaravilli, F.; Altmann, D.R.; Barker, G.J.; Miller, D.H. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann. Neurol. 2004, 56, 407–415. [Google Scholar] [CrossRef]
  70. Rausch, M.; Hiestand, P.; Baumann, D.; Cannet, C.; Rudin, M. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn. Reson. Med. 2003, 50, 309–314. [Google Scholar] [CrossRef]
  71. Ge, Y.; Grossman, R.I.; Udupa, J.K.; Babb, J.S.; Kolson, D.L.; McGowan, J.C. Magnetization transfer ratio histogram analysis of gray matter in relapsing-remitting multiple sclerosis. AJNR. Am. J. Neuroradiol. 2001, 22, 470–475. [Google Scholar]
  72. Caramanos, Z.; Narayanan, S.; Arnold, D.L. 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: A meta-analytic review. Brain 2005, 128, 2483–2506. [Google Scholar] [CrossRef] [Green Version]
  73. MacMillan, E.L.; Tam, R.; Zhao, Y.; Vavasour, I.M.; Li, D.K.; Oger, J.; Freedman, M.S.; Kolind, S.H.; Traboulsee, A.L. Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years. Mult. Scler. 2016, 22, 112–116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Kirov, I.I.; Tal, A.; Babb, J.S.; Herbert, J.; Gonen, O. Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS. Neurology 2013, 80, 39–46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Liu, T.; Chen, Y.; Thomas, A.M.; Song, X. CEST MRI with distribution-based analysis for assessment of early stage disease activity in a mouse model of multiple sclerosis: An initial study. NMR. Biomed. 2019, 32, e4139. [Google Scholar] [CrossRef]
  76. Nathoo, N.; Yong, V.W.; Dunn, J.F. Understanding disease processes in multiple sclerosis through magnetic resonance imaging studies in animal models. Neuroimage Clin. 2014, 4, 743–756. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Perazella, M.A. Current status of gadolinium toxicity in patients with kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4, 461–469. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  78. Kanda, T.; Ishii, K.; Kawaguchi, H.; Kitajima, K.; Takenaka, D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: Relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014, 270, 834–841. [Google Scholar] [CrossRef] [Green Version]
  79. Mehta, V.; Pei, W.; Yang, G.; Li, S.; Swamy, E.; Boster, A.; Schmalbrock, P.; Pitt, D. Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS ONE 2013, 8, e57573. [Google Scholar] [CrossRef]
  80. Liu, G.; Song, X.; Chan, K.W.; McMahon, M.T. Nuts and bolts of chemical exchange saturation transfer MRI. NMR. Biomed. 2013, 26, 810–828. [Google Scholar] [CrossRef]
  81. Wu, B.; Warnock, G.; Zaiss, M.; Lin, C.; Chen, M.; Zhou, Z.; Mu, L.; Nanz, D.; Tuura, R.; Delso, G. An overview of CEST MRI for non-MR physicists. EJNMMI. Phys. 2016, 3, 1–21. [Google Scholar] [CrossRef] [Green Version]
  82. Tain, R.W.; Scotti, A.M.; Cai, K. Improving the detection specificity of endogenous MRI for reactive oxygen species (ROS). J. Magn. Reson. Imaging 2019, 50, 583–591. [Google Scholar] [CrossRef]
  83. Tietze, A.; Blicher, J.; Mikkelsen, I.K.; Østergaard, L.; Strother, M.K.; Smith, S.A.; Donahue, M.J. Assessment of ischemic penumbra in patients with hyperacute stroke using amide proton transfer (APT) chemical exchange saturation transfer (CEST) MRI. NMR. Biomed. 2014, 27, 163–174. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Karaszewski, B.; Wardlaw, J.M.; Marshall, I.; Cvoro, V.; Wartolowska, K.; Haga, K.; Armitage, P.A.; Bastin, M.E.; Dennis, M.S. Measurement of brain temperature with magnetic resonance spectroscopy in acute ischemic stroke. Ann. Neurol. 2006, 60, 438–446. [Google Scholar] [CrossRef] [PubMed]
  85. Graham, S.H.; Chen, J.; Sharp, F.R.; Simon, R.P. Limiting ischemic injury by inhibition of excitatory amino acid release. J. Cereb. Blood. Flow. Metab. 1993, 13, 88–97. [Google Scholar] [CrossRef] [Green Version]
  86. Kimberly, W.T.; Wang, Y.; Pham, L.; Furie, K.L.; Gerszten, R.E. Metabolite profiling identifies a branched chain amino acid signature in acute cardioembolic stroke. Stroke 2013, 44, 1389–1395. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Melani, A.; Pantoni, L.; Corsi, C.; Bianchi, L.; Monopoli, A.; Bertorelli, R.; Pepeu, G.; Pedata, F. Striatal outflow of adenosine, excitatory amino acids, γ-aminobutyric acid, and taurine in awake freely moving rats after middle cerebral artery occlusion: Correlations with neurological deficit and histopathological damage. Stroke 1999, 30, 2448–2455. [Google Scholar] [CrossRef]
  88. Pascual, J.M.; Carceller, F.; Roda, J.M.; Cerdán, S. Glutamate, glutamine, and GABA as substrates for the neuronal and glial compartments after focal cerebral ischemia in rats. Stroke 1998, 29, 1048–1057. [Google Scholar] [CrossRef] [Green Version]
  89. Yang, M.; Wang, S.; Hao, F.; Li, Y.; Tang, H.; Shi, X. NMR analysis of the rat neurochemical changes induced by middle cerebral artery occlusion. Talanta 2012, 88, 136–144. [Google Scholar] [CrossRef]
  90. Alessandro Scotti, R.-W.T.; Li, W.; Zhou, X.J.; Cai, K. ROS detection by endogenous contrast MRI: Specificity and translational premises. In Proceedings of the 26th ISMRM, Honolulu, HI, USA, 22–24 April 2017. [Google Scholar]
  91. Tain, R.W.; Scotti, A.M.; Li, W.G.; Zhou, X.J.; Cai, K.J. Imaging short-lived reactive oxygen species (ROS) with endogenous contrast MRI. J. Magn. Reson. Imaging 2018, 47, 222–229. [Google Scholar] [CrossRef]
  92. Chan, P.H. Reactive oxygen radicals in signaling and damage in the ischemic brain. J. Cereb. Blood. Flow. Metab. 2001, 21, 2–14. [Google Scholar] [CrossRef]
  93. Haider, L.; Fischer, M.T.; Frischer, J.M.; Bauer, J.; Höftberger, R.; Botond, G.; Esterbauer, H.; Binder, C.J.; Witztum, J.L.; Lassmann, H. Oxidative damage in multiple sclerosis lesions. Brain 2011, 134, 1914–1924. [Google Scholar] [CrossRef] [Green Version]
  94. Su, C.; Xu, S.; Lin, D.; He, H.; Chen, Z.; Damen, F.C.; Ke, C.; Lv, X.; Cai, K. Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients. Eur. Radiol. 2022, 32, 101–111. [Google Scholar] [CrossRef] [PubMed]
  95. Zhang, J.; Zhu, W.; Tain, R.; Zhou, X.J.; Cai, K. Improved Differentiation of Low-Grade and High-Grade Gliomas and Detection of Tumor Proliferation Using APT Contrast Fitted from Z-Spectrum. Mol. Imaging Biol. 2018, 20, 623–631. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Flowchart of data processing steps in the DS-removed Omega plot method for quantifying in vivo tissue kex.
Figure 1. Flowchart of data processing steps in the DS-removed Omega plot method for quantifying in vivo tissue kex.
Biosensors 12 00815 g001
Figure 2. kex MRI based on the DS-removed Omega plots implemented on phantom protein solutions containing 20% (w/w) bovine serum albumin (BSA) in phosphate-buffered saline (PBS) at room temperature with pH titrated to 6.2, 6.6, 7.0 and 7.4. (A) T2-weighted image of the phantoms (B) A typical Omega plot, Mz/(M0 − Mz) versus 1/ω2 (ω = γB1), constructed from DS-removed Z-spectra for the pH 6.6 phantom. The linearity of the plot is clear. The x-intercept of the fit to the Omega-plot provides a direct readout of the exchange rate. (C) The constructed proton exchange rate maps. (D) The proton exchange rate values show that the exchange rate values increase linearly as pH increases. (E,F) The proton exchange rate values from the raw Z-spectra failed to distinguish different pH and did not show a linear dependency with pH values. (Reprinted with permission from Quant Imaging Med Surg. 2019; 9(10): 1686–96, Figure 5 (CC BY-NC-ND 4.0)).
Figure 2. kex MRI based on the DS-removed Omega plots implemented on phantom protein solutions containing 20% (w/w) bovine serum albumin (BSA) in phosphate-buffered saline (PBS) at room temperature with pH titrated to 6.2, 6.6, 7.0 and 7.4. (A) T2-weighted image of the phantoms (B) A typical Omega plot, Mz/(M0 − Mz) versus 1/ω2 (ω = γB1), constructed from DS-removed Z-spectra for the pH 6.6 phantom. The linearity of the plot is clear. The x-intercept of the fit to the Omega-plot provides a direct readout of the exchange rate. (C) The constructed proton exchange rate maps. (D) The proton exchange rate values show that the exchange rate values increase linearly as pH increases. (E,F) The proton exchange rate values from the raw Z-spectra failed to distinguish different pH and did not show a linear dependency with pH values. (Reprinted with permission from Quant Imaging Med Surg. 2019; 9(10): 1686–96, Figure 5 (CC BY-NC-ND 4.0)).
Biosensors 12 00815 g002
Figure 3. Different MRI images from a representative ischemic stroke patient showing the infarct lesion area. (a) T2-weighted fluid-attenuated inversion recovery (T2-FLAIR) image. (b) DWI. (c) kex MRI. The kex map reflects a larger extent of the infarct lesion with an elevated signal. (Reprinted by permission from J Neurosci Methods. 2020; (346), 108926. Figure 4).
Figure 3. Different MRI images from a representative ischemic stroke patient showing the infarct lesion area. (a) T2-weighted fluid-attenuated inversion recovery (T2-FLAIR) image. (b) DWI. (c) kex MRI. The kex map reflects a larger extent of the infarct lesion with an elevated signal. (Reprinted by permission from J Neurosci Methods. 2020; (346), 108926. Figure 4).
Biosensors 12 00815 g003
Figure 4. A total of 153 MS lesions in 16 MS patients were identified on kex images and compared with those on T2 weighted and gadolinium (Gd) enhanced MR images. Top row: A representative case, in which among the 6 lesions identified on the T2WI slice none showed Gd enhancement while 4 of them (black arrows) showed elevated kex. Bottom row: Categorization of all studied 153 MS lesions based on Gd-enhancement and kex MRI put them in three distinguished patterns. While all the Gd-enhancing lesions showed significant elevation in kex value compared to the normal-appearing white matter (NAWM), the non-Gd-enhancing lesions showed either a significant kex elevation (76%) or no kex elevation (24%) compared to NAWM. (Reprinted from J Magn Reson Imaging. 2020; 53(2), 408–415, Figures 4 and 5).
Figure 4. A total of 153 MS lesions in 16 MS patients were identified on kex images and compared with those on T2 weighted and gadolinium (Gd) enhanced MR images. Top row: A representative case, in which among the 6 lesions identified on the T2WI slice none showed Gd enhancement while 4 of them (black arrows) showed elevated kex. Bottom row: Categorization of all studied 153 MS lesions based on Gd-enhancement and kex MRI put them in three distinguished patterns. While all the Gd-enhancing lesions showed significant elevation in kex value compared to the normal-appearing white matter (NAWM), the non-Gd-enhancing lesions showed either a significant kex elevation (76%) or no kex elevation (24%) compared to NAWM. (Reprinted from J Magn Reson Imaging. 2020; 53(2), 408–415, Figures 4 and 5).
Biosensors 12 00815 g004
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Shaghaghi, M.; Cai, K. Toward In Vivo MRI of the Tissue Proton Exchange Rate in Humans. Biosensors 2022, 12, 815. https://doi.org/10.3390/bios12100815

AMA Style

Shaghaghi M, Cai K. Toward In Vivo MRI of the Tissue Proton Exchange Rate in Humans. Biosensors. 2022; 12(10):815. https://doi.org/10.3390/bios12100815

Chicago/Turabian Style

Shaghaghi, Mehran, and Kejia Cai. 2022. "Toward In Vivo MRI of the Tissue Proton Exchange Rate in Humans" Biosensors 12, no. 10: 815. https://doi.org/10.3390/bios12100815

APA Style

Shaghaghi, M., & Cai, K. (2022). Toward In Vivo MRI of the Tissue Proton Exchange Rate in Humans. Biosensors, 12(10), 815. https://doi.org/10.3390/bios12100815

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop